Close Menu

Epstein-Barr virus

The study, slated to begin in the first half of 2021, follows recent discussion with the FDA and promising Phase II data presented at the ASH annual meeting.

Researchers are making improvements to viral-DNA detection methods and are exploring applications not just for screening but also disease monitoring.